Pathogenes Inc.

New updates for the treatment of EPM 2013

We are in the process of licensing two products for the treatment of EPM and residual (or recurrent signs) commonly found after infections.  Both products are in the FDA MUMS program.  Our products are produced in an FDA licensed facility.

We have active trials using these products.  Some trials are placebo contolled and some are not.  Please call to discuss our programs.